The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary

Yoshino, Takayuki; Van Cutsem, Eric; Eng, Cathy; Kim, Tae Won; Wasan, Harpreet; Kopetz, Scott; Tabernero, Josep

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Yoshino, Takayuki
dc.contributor.author	Van Cutsem, Eric
dc.contributor.author	Eng, Cathy
dc.contributor.author	Kim, Tae Won
dc.contributor.author	Wasan, Harpreet
dc.contributor.author	Kopetz, Scott
dc.contributor.author	Tabernero, Josep
dc.date.accessioned	2025-07-11T07:29:26Z
dc.date.available	2025-07-11T07:29:26Z
dc.date.issued	2025
dc.identifier.citation	Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, et al. The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary. Futur Oncol. 2025;21(13):1541-52.
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/11351/13399
dc.description	Quimioteràpia; Càncer colorectal metastàtic; Mutació
dc.description.sponsorship	This manuscript was funded by Pfizer.
dc.language.iso	eng
dc.publisher	Taylor & Francis
dc.relation.ispartofseries	Future Oncology;21(13)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Anomalies cromosòmiques
dc.subject	Recte - Càncer - Tractament
dc.subject	Còlon - Càncer - Tractament
dc.subject	Quimioteràpia combinada
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject.mesh	Mutation
dc.subject.mesh	Colorectal Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Antibodies, Monoclonal
dc.subject.mesh	/therapeutic use
dc.title	The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1080/14796694.2025.2491290
dc.subject.decs	mutación
dc.subject.decs	neoplasias colorrectales
dc.subject.decs	/farmacoterapia
dc.subject.decs	protocolos de quimioterapia antineoplásica combinada
dc.subject.decs	anticuerpos monoclonales
dc.subject.decs	/uso terapéutico
dc.relation.publishversion	https://doi.org/10.1080/14796694.2025.2491290
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Kopetz S] University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Eng C] Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. [Kim TW] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Wasan HS] Hammersmith Hospital, Division of Cancer, Imperial College London, London, UK. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain
dc.identifier.pmid	40391894
dc.rights.accessrights	info:eu-repo/semantics/openAccess